PTC Therapeutics (PTCT) Stock Price, News & Analysis

Company Overview

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets. The company also commercializes Emflaza (deflazacort) for patients with Duchenne muscular dystrophy, expanding its portfolio in neuromuscular disease. PTC’s pipeline extends into areas such as central nervous system disorders and metabolic diseases, with programs advancing through clinical and preclinical stages to address rare forms of Rett syndrome, tyrosinemia and other genetic conditions.

Headquartered in South Plainfield, New Jersey, PTC operates a global network encompassing commercial, research and manufacturing facilities across North America, Europe and Asia. The company’s leadership team is led by Stuart W. Peltz, Ph.D., who has served as Chief Executive Officer since co-founding the business. Under his guidance, PTC has established strategic collaborations and regulatory approvals that bolster its presence in key international markets, reflecting a commitment to bringing innovative therapies to patients around the world.

Key Stats

• Today's Range: $59.60 to $61.95
• 50-Day Range: $43.30 to $61.09
• 52-Week Range: $34.57 to $62.18
• Volume: 2.26 million shs
• Average Volume: 1.16 million shs
• Market Capitalization: $4.82 billion
• P/E Ratio: 8.70
• Dividend Yield: N/A
• Price Target: $69.00
• Consensus Rating: Moderate Buy

PTC Therapeutics Stock Analysis - MarketRank™

PTC Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 281st out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 9 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

PTC Therapeutics has a consensus price target of $69.00, representing about 13.8% upside from its current price of $60.65.

Amount of Analyst Coverage

PTC Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PTC Therapeutics is 8.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 268.10.

Price to Earnings Ratio vs. Sector

The P/E ratio of PTC Therapeutics is 8.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 57.40.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.85% of the float of PTC Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

PTC Therapeutics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in PTC Therapeutics has recently increased by 2.15%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PTC Therapeutics does not currently pay a dividend.

Dividend Growth

PTC Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.38

Percentage of Shares Shorted

8.85% of the float of PTC Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

PTC Therapeutics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in PTC Therapeutics has recently increased by 2.15%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.93

News Sentiment

PTC Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for PTC Therapeutics this week, compared to 10 articles on an average week.

Search Interest

Only 2 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,640,615.00 in company stock.

Percentage Held by Insiders

Only 5.50% of the stock of PTC Therapeutics is held by insiders.

PTCT Stock Analysis - Frequently Asked Questions

How have PTCT shares performed this year?

PTC Therapeutics' stock was trading at $45.14 at the start of the year. Since then, PTCT stock has increased by 34.4% and is now trading at $60.65.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its earnings results on Thursday, August, 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.24. The company's revenue was down 4.2% on a year-over-year basis.
Read the conference call transcript.

Who are PTC Therapeutics' major shareholders?

Top institutional investors of PTC Therapeutics include Armistice Capital LLC (5.96%), State Street Corp (3.77%), Geode Capital Management LLC (2.44%) and Man Group plc (0.85%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Neil Gregory Almstead, Lee Scott Golden, Eric Pauwels, Pierre Gravier, Christine Marie Utter, Emily Luisa Hill, Allan Steven Jacobson, David P Southwell, Jerome B Zeldis, Emma Reeve, Alethia Young and Stephanie Okey.
View institutional ownership trends.

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTCT
• CIK: 1070081
• Web: www.ptcbio.com
• Phone: (908) 222-7000
• Fax: 908-222-7231
• Employees: 1,410
• Year Founded: 1998

Price Target and Rating

• Average Price Target for PTC Therapeutics: $69.00
• High Price Target: $118.00
• Low Price Target: $42.00
• Potential Upside/Downside: +13.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.53
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.97
• Trailing P/E Ratio: 8.70
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$363.30 million
• Net Margins: 35.65%
• Pretax Margin: 37.74%
• Return on Equity: -106.31%
• Return on Assets: 30.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.62
• Quick Ratio: 3.57

Sales & Book Value

• Annual Sales: $806.78 million
• Price / Sales: 5.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($14.24) per share
• Price / Book: -4.26

Miscellaneous

• Outstanding Shares: 79,440,000
• Free Float: 75,069,000
• Market Cap: $4.82 billion
• Optionable: Optionable
• Beta: 0.53